Scilex (SCLX) - Price-to-Projected Revenue Ratio

Public company logo of Scilex Holding Company (SCLX)

The risks of narrow specialization for Scilex Holding Company are mitigated by the successful market launch of patented patches. The projected market cap-to-revenue ratio visualizes this trend, where 0.10 expresses the current value of the metric. The financial foundation relies on the commercialization of ZTlido and pain-relief injections. A positive trend is fueled by demand for non-opioid treatments and the progress of the drug SP-102.

SCLX scilexholding.com: Price-to-Projected Revenue Ratio in the range 04/28/2023 - 11/18/2026

Analytical breakdowns for Scilex Holding Company

- current price and projected stock value:
Fundamental company valuation:Scilex Holding SCLX
Product sample of Scilex Holding Company

Forward P/S measures market capitalization relative to projected revenue, allowing investors to assess an asset's degree of overvaluation during periods of high volatility. By analyzing the expected P/S of Scilex Holding Company (SCLX), one can determine a minimum-risk entry point, given that stable demand for SCLX pain medications ensures predictable cash flows regardless of economic cycles.

Main competitors

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|TVGN - Market Cap to Expected Sales Ratio|ACOG (Alpha Cognition Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple cogrx.com (CGTX)|Price-to-Projected Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Market Cap to Expected Sales Ratio Cassava Sciences|Forward P/S Multiple ASRT (Assertio Holdings)|COYA - Forward Price-to-Revenue Multiple|vistagen.com - Forward P/S Multiple|OVID: Price-to-Projected Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Projected Revenue Ratio|CervoMed Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PEPG (PepGen Inc)|Forward P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Projected Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Projected Revenue|Grace Tx - Forward P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals, Inc.|Forward Price-to-Revenue Multiple metaviatx.com (MTVA)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio, Inc. - Forward Price-to-Revenue Multiple|bionomics.com.au (NEUP) - Market Cap to Future Revenue Ratio|Minerva - Forward P/S Multiple|Forward Price to Sales ATHA (Athira Pharma Inc)|ADXN: Forward P/S Multiple|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|PTIX (Protagenic Therapeutics) - Price to Expected Revenue Ratio|Forward P/S Multiple KTTA|Market Cap to Expected Sales Ratio Cortigent|Forward P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple